DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lexaria Bioscience...
Tuesday U.S. Economic Lookahead NFIB optimism index (June) Consumer credit (May) ...
KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...
KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®
Lexaria executing a triple-pronged strategy in obesity and diabetes